We have hypothesized that the midbrain dopamine (DA) neurons are a target for insulin action in the central nervous system (CNS). In support of this hypothesis, we have previously demonstrated that direct intracerebroventricular infusion of insulin results in an increase in mRNA levels for the DA reuptake transporter (DAT). In this study, 24- to 36-hour food deprivation was used as a model of decreased CNS insulin levels, to test whether DAT mRNA levels, DAT protein concentration or DAT functional activity would be decreased. DAT mRNA levels, assessed by in situ hybridization, were significantly decreased in the ventral tegmental area/substantia nigra pars compacta (VTA/SNc) (77 ± 7% of controls, p < 0.05) of food-deprived (hypoinsulinemic) rats. Binding of a specific high-affinity DAT ligand (125I-RTI-121) to membranes from brain regions of fasted or free-feeding rats provided an estimate of DAT protein, which was unchanged in both of the major terminal projection fields, the striatum and nucleus accumbens (NAc). In addition, we utilized the rotating disk electrode voltametry technique to assess possible changes in the function of the DAT in fasting (hypoinsulinemic) rats. The Vmax of DA uptake was significantly decreased (87 ± 7% of control, p < 0.05), without a change in the Km of uptake, in striatum from fasted rats. In vitro incubation with a physiological concentration (1 nM) of insulin resulted in an increase of striatal DA uptake to control levels. We conclude that striatal DAT function can be modulated by fasting and nutritional status, with a contribution by insulin.

Keywords:
Insulin, Dopamine transporter, Catecholamines, Food deprivation, In situ hybridization
1.
Strange PG: New insights into dopamine receptors in the central nervous system. Neurochem Int 1993;22:223–236.
2.
Creese I, Burt DR, Snyder SH: Biochemical actions of neuroleptic drugs: Focus on the dopamine receptor; in Iversen LL, Iversen SD, Snyder SH (eds): Handbook of Pharmacology. New York, Plenum Press, 1978, vol 10, pp 37–90.
3.
Baldessarini RJ, Tarsy D: Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs. Annu Rev Neurosci 1980;3:23–41.
4.
Baldessarini RJ, Tarsy D: Pathophysiological basis of tardive dyskinesia. Adv Biochem Psychopharm 1980;24:451–455.
5.
Kuhar MJ, Ritz MC, Boja JW: The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991;14:299–302.
6.
Koob GF: Drugs of abuse: anatomy, pharmacology, and function of reward pathways. Trends Pharm Sci 1992;13:177–184.
7.
Hitri A, Hurd YL, Wyatt RJ, Deutsch SI: Molecular, functional and biochemical characteristics of the dopamine transporter: Regional differences and clinical relevance. Clin Neuropharm 1994;17:1–22.
8.
Amara SG, Kuhar MJ: Neurotransmitter transporters: Recent progress. Annu Rev Neurosci 1993;16:73–93.
9.
Giros G, Jaber M, Jones SR, Wightman RM, Caron MG: Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996;379:606–612.
10.
Gainetdinov RR, Fumagalli F, Jones SR, Caron MG: Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter. J Neurochem 1997;69:1322–1325.
11.
Bannon MJ, Granneman JG, Kapatos G: The dopamine transporter: Potential involvement in neuropsychiatric disorders; in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven, 1995, pp 179–188.
12.
Povlock SL, Amara SG: The structure and function of norepinephrine, dopamine and serotonin transporters; in Reith MEA (ed): Neurotransmitter Transporters. Totowa, Humana, 1997, pp 1–28.
13.
Chu PC, Lin MT, Shian LR, Leu SY: Alterations in physiologic functions and in brain monoamine content in streptozotocin-diabetic rats. Diabetes 1986;35:481–485.
14.
Leedom LJ, Meehan WP: The psychoneuroendocrinology of diabetes mellitus in rodents. Psychoneuroendocrinology 1989;14:275–294.
15.
Shimomura Y, Shimizu H, Takahashi M, Uehara Y, Kobayashi I, Kobayashi S: Ambulatory activity and dopamine turnover in streptozotocin-induced diabetic rats. Exp Clin Endocrinol 1990;95:385–388.
16.
Bellush LL, Reid SG: Altered behavior and neurochemistry during short term insulin withdrawal in streptozotocin-diabetic rats. Diabetes 1991;40:217–222.
17.
Sandyk R: The relationship between diabetes mellitus and Parkinson’s disease. Int J Neurosci 1993;69:125–130.
18.
Heaton JP, Varrin SJ: Effects of streptozotocin-induced diabetes on dopaminergic functioning in the rat: Analysis of yawning behavior. Pharm Biochem Behav 1993;44:601–604.
19.
Figlewicz DP, Brot MD, McCall AL, Szot P: Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: A molecular study. Brain Res 1996;736:54–60.
20.
Figlewicz DP, Szot P, Chavez M, Woods SC, Veith RC: Intraventricular insulin increases dopamine transporter mRNA in rat VTA/substantia nigra. Brain Res 1994;644:331–334.
21.
Bell SM, Steward RB, Thompson SC, Meisch RA: Food-deprivation increases cocaine-induced conditioned place preference and locomotor activity in rats. Psychopharmacology 1997;131:1–8.
22.
Carroll ME, Meisch RA: Increased drug-reinforced behavior due to food deprivation; in Thompson T, Dews PB, Barrett JE (eds): Advances in Behavioral Pharmacology. New York, Academic Press, 1984, pp 47–88.
23.
Morgan DR, Lazarow A: Immunoassay of insulin: Two-antibody system. Diabetes 1963;12:115–126.
24.
Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates, ed 2. Orlando, Academic Press, 1986.
25.
Staley JK, Boja JW, Carroll FI, Seltzman HH, Wyrick CD, Lewin AH, Abraham P, Marsh DC: Mapping dopamine transporters in the human brain with novel selective cocaine analog [125I]RTI-121. Synapse 1995;21:364–372.
26.
Meiergerd SM, Schenk JO: Measurement of time-resolved kinetics of biogenic amine release and transporter activity by rotating disk electrode voltammetry in vitro; in Boulton AA, Baker GB, Adams RN (eds): Neuromethods. Voltammetric Methods in Brain Systems. Totowa, Humana, 1995, vol 27, pp 305–337.
27.
Schenk JO, Patterson TA, McElvain JS: Rotating disk voltammetric measurements in neurobiology and neuropharmacology. Trends Anal Chem 1990;9:325–330.
28.
McElvain JS, Schenk JO: Blockade of dopamine autoreceptors by haloperidol and the apparent dynamics of potassium-stimulated endogenous release of dopamine from and reuptake into striatal suspensions in the rat. Neuropharmacology 1992;31:649–659.
29.
Meiergerd SM, Hooks SM, Schenk JO: The striatal transporter for dopamine in the rat may be kinetically up-regulated following 3 weeks of withdrawal from cocaine self-administration. J Neurochem 1994;63:1277–1281.
30.
Meiergerd SM, Patterson TA, Schenk JO: D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J Neurochem 1993;61:764–767.
31.
Havilcek LL, Crain TK: Practical Statistics for the Physical Sciences. Washington, American Chemical Society, 1988.
32.
Stein WD: Transport and Diffusion Across Cell Membranes. San Diego, Academic Press, 1986.
33.
Stein WD: Kinetics of transport: Analyzing, testing, and characterizing models using kinetic approaches. Adv Enzymol 1989;171:23–62.
34.
Pifl C, Giros B, Caron MG: Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci 1993;13:4246–4253.
35.
Burnette WB, Danna Bailey M, Kokoy S, Blakely RD, Trowbridge CG, Justice JB Jr: Human norepinephrine transporter kinetics using rotating disk electrode voltammetry. Anal Chem 1996;68:2932–2938.
36.
Ramamoorthy S, Cool DR, Mahesh VB, Leibach FH, Melikian HE, Blakely RD, Ganapathy V: Regulation of the human serotonin transporter. Cholera toxin-induced stimulation of serotonin uptake in human placental choriocarcinoma cells is accompanied by increased serotonin transporter mRNA levels and serotonin transporter-specific ligand binding. J Biol Chem 1993;268:21626–21631.
37.
Liu F, McConkey F, Man HY, Lee FJS, Levey AI, Wang YT, Pristupa ZB, Niznik HB: Second messenger mediated translocation of the human dopamine transporter. Soc Neurosci Abstr 1997;23:692.
38.
Corey JL, Davidson N, Lester HA, Brecha N, Quick MW: Protein kinase C modulates the activity of a cloned γ-aminobutyric acid transporter expressed in Xenopus oocytes via regulated subcellular redistribution of the transporter. J Biol Chem 1994;269:14759–14767.
39.
Hanson ES, Levin N, Dallman MF: Elevated corticosterone is not required for the rapid induction of neuropeptide Y gene expression by an overnight fast. Endocrinology 1997;138:1041–1047.
40.
Patterson TA, Figlewicz Lattemann D: Acute corticosterone incubation in vitro inhibits the function of the dopamine transporter in nucleus accumbens but not the striatum of the rat brain: An in vitro voltammetric study. Soc Neurosci Abst 1997;23:693.
41.
Fleckenstein AE, Pogun S, Carroll FI, Kuhar MJ: Recovery of dopamine transporter binding and function after intrastriatal administration of the irreversible inhibitor RTI-76 [3 B-(3p-chlorophenyl) tropan-2 beta-carboxylic acid p-isothiocyanatophenylethyl ester hydrochloride]. J Pharm Exp Ther 1996;279:200–206.
42.
Silvia CP, Jaber M, King GR, Ellinwood EH, Caron MG: Cocaine and amphetamine elicit differential effects in rats with a unilateral injection of dopamine transporter antisense oligodeoxynucleotides. Neuroscience 1997;76:737–747.
43.
Zhou D, Huether G, Wiltfang J, Hajak G, Ruther E: Serotonin transporters in the rat frontal cortex: Lack of circadian rhythmicity but down-regulation by food restriction. J Neurochem 1996;67:656–661.
44.
Cheatham B, Kahn CR: Insulin action and the insulin signaling network. Endo Rev 1995;16:117–142.
45.
Simon JR, Bare DJ, Ghetti B, Richter JA: A possible role for tyrosine kinases in the regulation of the neuronal dopamine transporter in mouse striatum. Neurosci Lett 1997;224:201–205.
46.
Huff RA, Vaughan RA, Kuhar MJ, Uhl GR: Phorbol esters increase dopamine transporter phosphorylation and decrease transport Vmax. J Neurochem 1997;68:225–232.
47.
Unger J, McNeill TH, Moxley RT, White M, Moss A, Livingston JN: Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neurosciences 1989;31:143–157.
48.
Werther GA, Hogg A, Oldfield BJ, McKinley MJ, Figdor R, Allen AM, Mendelsohn FAO: Localization and characterization of insulin receptors in rat brain and pituitary gland using in vitro autoradiography and computerized densitometry. Endocrinology 1987;121:1562–1570.
49.
Moroo I, Yamada T, Makino H, Tooyama I, McGeer PL, McGeer EG: Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson’s disease. Acta Neuropathol Berlin 1994;87:343–348.
50.
Takahashi M, Yamada T, Tooyama I, Kimura H, Yamamoto T, Okada H: Insulin receptor mRNA in the substantia nigra in Parkinson’s disease. Neurosci Lett 1996;204:201–204.
51.
Uhl GR, Walther D, Mash D, Faucheux B, Javoy-Agid F: Dopamine transporter messenger RNA in Parkinson’s disease and control substantia nigra neurons. Ann Neurol 1994;35:494–498.
52.
Thompson TL, Moss RL: Estrogen regulation of dopamine release in the nucleus accumbens: Genomic- and nongenomic-mediated effects. J Neurochem 1994;62:1750–1756.
53.
Fumagalli F, Jones SR, Caron MG, Seidler FJ, Slotkin TA: Expression of mRNA coding for the serotonin transporter in aged vs. young rat brain: Differential effects of glucocorticoids. Brain Res 1996;719:225–228.
54.
Miller KJ, Hoffman BJ: Adenosine A3 receptors regulate serotonin transport via nitric oxide and cGMP. J Biol Chem 1994;44:27351–27356.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.